Group 1 - The China-Shanghai Cooperation Organization (SCO) has officially launched three cooperation platforms focusing on energy, green industries, and digital economy to enhance collaboration and promote sustainable development among member states [2] - In August, the number of new A-share accounts reached 2.65 million, a year-on-year increase of 165%, significantly surpassing the same period last year [2] - The software and information technology service industry in China reported a revenue of 83,246 billion yuan in the first seven months of 2025, with a year-on-year growth of 12.3% [2] - The Beijing Stock Exchange reported that all 274 listed companies completed their semi-annual reports, with total operating income of 92.064 billion yuan, reflecting a year-on-year growth of 6.01% [2] - Major food delivery platforms in China, including Meituan, Alibaba, and JD, reported significant declines in net profits due to increased marketing expenses during a competitive period, with Meituan's net profit dropping nearly 90% [2] Group 2 - The Ministry of Finance and the State Taxation Administration of China issued new tax policies to support the management of state-owned equity and cash income for social security fund transfers [2] - The net inflow of southbound funds in Hong Kong reached 9.281 billion HKD, marking a record high since the launch of the mutual market access mechanism [2] - The People's Bank of China reported a net liquidity injection of 300 billion yuan through medium-term lending facilities in August [2] - The IPO application for Yuzhu Technology is expected to be submitted to the stock exchange between October and December, with quadruped and humanoid robots projected to account for 65% and 30% of sales in 2024, respectively [2]

Group 1 - The company announced the successful completion of the first subject enrollment and administration in the Phase II clinical trial of "GB08 Injection," developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd [1][2] - "GB08 Injection" is the company's first independently developed Class I innovative drug, designed to address the needs of clinical patients with growth hormone deficiency in children, utilizing DNA recombinant technology to enhance safety and patient compliance [1][2] - The clinical trial aims to evaluate the efficacy and safety of "GB08 Injection" in treating children with growth hormone deficiency, with ethical approval obtained from Zhejiang University School of Medicine Affiliated Children's Hospital [2] Group 2 - The successful enrollment of the first subject in the Phase II clinical trial of "GB08 Injection" is not expected to have a significant impact on the company's recent financial status or operating performance [3]

Group 1 - The company announced the successful enrollment of the first subject in the Phase II clinical trial of GB08 injection, which is an innovative drug developed for children with growth hormone deficiency [1][2] - GB08 injection is the company's first self-developed Class I innovative drug, utilizing DNA recombinant technology to enhance safety and patient compliance [1][2] - The clinical trial aims to evaluate the efficacy and safety of GB08 injection in treating children with growth hormone deficiency, with ethical approval obtained from Zhejiang University School of Medicine [2] Group 2 - The successful enrollment of the first subject in the clinical trial is not expected to have a significant impact on the company's recent financial status or operating performance [3]

Major Events - Dongxin Co., Ltd. completed its verification work and will resume trading on September 3 after being suspended due to abnormal stock price fluctuations [4] - Tianpu Co., Ltd. may apply for a trading suspension if its stock price continues to rise abnormally, as it has experienced a cumulative increase of 100% over eight consecutive trading days [5] - Shangwei New Materials has seen its stock price rise by 1154.5% from July 9 to September 2, indicating a significant deviation from its fundamental performance [7] - Yinglian Co., Ltd. is in the early stages of planning a capital increase for its wholly-owned subsidiary, with no formal agreements signed yet [8] - Kexing Pharmaceutical has completed the first patient enrollment for the Phase II clinical study of its GB08 injection, a long-acting growth hormone [9] - WuXi AppTec plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary for organizational optimization [10] - Zhonglai Co., Ltd. announced the resignation of its chairman due to age reasons, with no shares held by him at the time of resignation [11] - Zhaoxin Co., Ltd. reported no significant changes in its internal and external operating environment [12] - Kuangda Technology is planning a change of control, leading to a continued suspension of its stock [14] - DiAo Micro announced the launch of its eUSB repeater product, filling a domestic gap and supporting its entry into the USB4.0 market [15] - Jinbei Automotive plans to invest 240 million yuan in an automotive industry investment fund focusing on electrification and intelligentization [16] - Junshi Biosciences received approval for clinical trials of its JT118 injection, a vaccine aimed at preventing monkeypox virus infection [17] - Kaidi Co., Ltd. reported that its robotics business is still in the development stage and has not yet generated revenue [18] - China Ping An plans to cancel 103 million A-shares, reducing its total share capital [19] - China National Petroleum Corporation intends to transfer 541 million A-shares to China Mobile Group to deepen strategic cooperation [20] Performance Overview - Seres reported a 19.57% year-on-year increase in new energy vehicle sales in August, with production reaching 43,069 units [21] - Qianli Technology's total vehicle sales in August increased by 168.55% year-on-year, although new energy vehicle sales decreased by 15.93% [22] - Guangzhou Port expects a 1.2% year-on-year increase in container throughput for August, with total cargo throughput also projected to rise [23] Shareholding Changes - Nuowei Zhan's shareholder, Guoshou Chengda, plans to reduce its stake by up to 3% due to funding needs [24][25] Buybacks - CATL has repurchased 8.69 million A-shares, accounting for 0.1973% of its total A-share capital, with a total transaction amount of 2.131 billion yuan [26] Financing Activities - Fulai New Materials plans to raise no more than 710 million yuan through a private placement to fund expansion projects [27] Strategic Partnerships - Pairui Co., Ltd. signed a strategic cooperation agreement with Xi'an Power Electronics Research Institute to jointly develop power devices [28] - Youxunda is a candidate for a tender project with China Southern Power Grid, with a pre-bid amount of approximately 161 million yuan [29]

Group 1 - Daoshi Technology's subsidiary Hong Kong Jiana invested $30 million in Brain Family Inc. to acquire minority shareholder rights through Pre-B round preferred shares [1] - Brain Family Inc. is a leading company in brain-computer interface technology with unique technical barriers and commercialization capabilities [1] - Daoshi Technology aims to enhance its "AI + new materials" ecosystem by leveraging Brain Family's experience in medical rehabilitation, educational consumption, and human-computer interaction [1] Group 2 - Sinovac Biotech's subsidiary completed the first subject enrollment for the Phase II clinical study of GB08 injection, a long-acting growth hormone for children with growth hormone deficiency [2] - The GB08 injection is the company's first independently developed Class I innovative drug [2] Group 3 - Heng Rui Medicine's subsidiary received approval for clinical trials of SHR-A2009, an antibody-drug conjugate targeting HER3, with no similar drugs approved globally [3] Group 4 - DiAo Microelectronics launched its self-developed high-performance eUSB repeater product, which supports bidirectional conversion between eUSB2 and USB2 signal schemes [4] - The product is designed for IoT, consumer electronics, and automotive electronics, enhancing the company's competitiveness in high-speed interface chips [4] Group 5 - Dongxin Co. announced the completion of its stock review and will resume trading on September 3 after a temporary suspension due to abnormal stock price fluctuations [5] - The company stated that its fundamentals and main business have not changed significantly [5] Group 6 - Junshi Biosciences received approval for clinical trials of JT118 injection, a "two-in-one" recombinant protein vaccine for monkeypox virus prevention, with no approved vaccines in the domestic market [6] Group 7 - Seres reported a 19.57% year-on-year increase in new energy vehicle sales in August, with production reaching 43,069 units and sales at 43,262 units [7][8] Group 8 - CATL has repurchased 8.69 million A-shares, totaling 2.131 billion yuan, with plans to continue the buyback based on market conditions [9] Group 9 - *ST Tianmao announced a cash option for shareholders during the period from September 15 to September 19, allowing them to exercise cash options at a price of 1.6 yuan per share [10]

Group 1 - The core point of the announcement is that Kexing Biopharmaceutical Co., Ltd. has successfully completed the enrollment of the first subject in the Phase II clinical trial of its self-developed GB08 injection, which is aimed at treating children with growth hormone deficiency [1][2] - GB08 injection is the company's first independently developed Class I innovative drug, designed as a long-acting growth hormone based on the needs of clinical patients [1][2] - The clinical trial for GB08 injection has received ethical approval from Zhejiang University School of Medicine Affiliated Children's Hospital, and the trial is a multi-center, randomized, open-label, positive-controlled Phase II/III study [2] Group 2 - The successful enrollment of the first subject in the Phase II clinical trial is not expected to have a significant impact on the company's recent financial status or operating performance [2] - The company will continue to monitor the progress of the GB08 injection and fulfill its disclosure obligations in accordance with relevant regulations [2]

格隆汇9月2日丨科兴制药(688136.SH)公布，公司全资子公司深圳科兴药业有限公司（以下简称"深圳科 兴"）研发的"GB08注射液"II期临床研究成功完成首例受试者入组给药。公司子公司深圳科兴开展的临 床试验"评价GB08注射液治疗儿童生长激素缺乏症受试者的有效性和安全性的多中心、随机、开放、阳 性对照的II/III期临床研究"于2025年7月获得临床试验组长单位浙江大学医学院附属儿童医院的伦理批件 （批件号：2025-IEC-0009-P-01），并已于近日完成首例受试者入组给药。 GB08注射液是公司首个自主研发的I类创新药，是公司根据临床患者需求、基于儿童生长激素缺乏症而 自主研发的一款Fc融合蛋白长效化生长激素，公司GB08注射液按治疗用生物制品1类"创新型生物制 品"申报。 ...

Core Viewpoint - The announcement highlights the successful completion of the first patient enrollment and dosing in the Phase II clinical study of "GB08 Injection," an innovative drug developed by the company's wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd [1] Group 1: Product Development - GB08 Injection is the company's first independently developed Class I innovative drug targeting growth hormone deficiency in children [1] - The drug is based on the clinical needs of patients and utilizes DNA recombinant technology to connect the human growth hormone (hGH) gene with the IgG4 Fc segment gene, resulting in a novel drug with a homologous dimeric protein structure [1] - The innovative drug significantly enhances product safety, patient convenience, and adherence to treatment [1] Group 2: Market Potential - If successfully developed and launched, GB08 Injection will provide new treatment options for patients suffering from growth hormone deficiency in children [1]

Core Viewpoint - The announcement highlights the successful completion of the first subject enrollment and administration in the Phase II clinical trial of "GB08 Injection," developed by the company's wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. [1] Group 1 - The clinical trial aims to evaluate the efficacy and safety of GB08 Injection for treating children with growth hormone deficiency [1] - This trial is a multi-center, randomized, open-label, positive-controlled Phase II/III clinical study [1] - The ethical approval for the trial has been obtained recently, and the first subject has been enrolled and administered [1] Group 2 - The trial is not expected to have a significant impact on the company's recent financial status and operating performance [1]